{"id":"meropenem-injection","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"3-8%","effect":"Nausea"},{"rate":"2-5%","effect":"Vomiting"},{"rate":"1-3%","effect":"Rash"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-4%","effect":"Phlebitis at injection site"},{"rate":"<1%","effect":"Seizures (in meningitis or renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it effective for serious infections caused by susceptible organisms.","oneSentence":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:28.785Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including intra-abdominal infections"},{"name":"Meningitis"},{"name":"Pneumonia"},{"name":"Sepsis"},{"name":"Febrile neutropenia"}]},"trialDetails":[{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT06672276","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria","enrollment":32},{"nctId":"NCT07314281","phase":"PHASE4","title":"Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever","status":"RECRUITING","sponsor":"Indus Hospital and Health Network","startDate":"2025-04-22","conditions":"Enteric Fever","enrollment":40},{"nctId":"NCT03452839","phase":"PHASE4","title":"Bolus Versus Continuous Infusion of Meropenem","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2018-06-05","conditions":"Antibiotic Resistant Infection, Critical Illness","enrollment":607},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT02687906","phase":"PHASE1","title":"Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","startDate":"2016-07","conditions":"Bacterial Infections","enrollment":39},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06841731","phase":"PHASE2","title":"A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-03","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)","enrollment":100},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":"Mental Health Issue","enrollment":80},{"nctId":"NCT06072222","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT06072248","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT05204368","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","status":"UNKNOWN","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-03-30","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":780},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT04553367","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT05340530","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04","conditions":"Infections","enrollment":56},{"nctId":"NCT04555798","phase":"PHASE1, PHASE2","title":"Effect of Arterio-venous ECMO on Severe Sepsis and ARDS","status":"COMPLETED","sponsor":"Mohamed Gaber Allam","startDate":"2022-02-01","conditions":"Patients With Respiratory Failure and Shocked","enrollment":100},{"nctId":"NCT04370145","phase":"PHASE4","title":"Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2021-05-01","conditions":"Cholangitis, Secondary Biliary, Treatment Compliance, Antibodies Drug Specific","enrollment":160},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT04154722","phase":"PHASE4","title":"Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2019-06-20","conditions":"Typhoid Fever","enrollment":126},{"nctId":"NCT04671589","phase":"PHASE4","title":"Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.","status":"UNKNOWN","sponsor":"Mabaret Al-Asafara Hospitals","startDate":"2021-06","conditions":"Drug Toxicity","enrollment":48},{"nctId":"NCT04402359","phase":"","title":"Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2018-07-05","conditions":"Ventilator Associated Pneumonia","enrollment":200},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT03645668","phase":"PHASE4","title":"Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-30","conditions":"Sepsis","enrollment":80},{"nctId":"NCT03571711","phase":"","title":"Meropenem Pharmacokinetics in Spontaneous Bacterial Peritonitis","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2018-06-28","conditions":"Peritonitis Bacterial, Liver Cirrhosis","enrollment":15},{"nctId":"NCT02168946","phase":"PHASE3","title":"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2014-07","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia","enrollment":77},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT02615041","phase":"PHASE4","title":"The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia","status":"COMPLETED","sponsor":"Sutep Jaruratanasirikul","startDate":"2004-01","conditions":"Ventilator-Associated Pneumonia","enrollment":9},{"nctId":"NCT02344563","phase":"PHASE4","title":"Bioequivalence of Two Formulations of Meropenem Intravenous Injection","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2014-09","conditions":"Healthy","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tinidazole injection","meropenem,MEPEM","Supportive care as fluids and securing airway if needed","meroneum","penro"],"phase":"marketed","status":"active","brandName":"Meropenem Injection","genericName":"Meropenem Injection","companyName":"Institute of Liver and Biliary Sciences, India","companyId":"institute-of-liver-and-biliary-sciences-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including intra-abdominal infections, Meningitis, Pneumonia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}